See how Apple Inc. and AbbVie Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$333.74
NasdaqGS
Apple Inc. is one of the world’s largest companies, offering a broad portfolio of hardware and software products for both consumers and businesses. The iPhone accounts for the majority of Apple’s revenue, while products such as the Mac, iPad, and Apple Watch are built around the iPhone as the centerpiece of a wide-reaching software ecosystem. Over time, Apple has expanded its offerings with new services and applications, including streaming video, subscription bundles, and augmented reality. The company designs its own software and semiconductors, while relying on manufacturing partners such as Foxconn and TSMC to produce its devices and chips. Slightly less than half of Apple’s sales are generated through its flagship retail stores, with most revenue coming indirectly through partnerships and distribution channels.
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.